Nascent Biotech, Inc. (NBIO)

OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Mar 9, 2026, 11:37 AM EST
-96.67%
Market Cap 51.85K
Revenue (ttm) n/a
Net Income (ttm) -1.92M
Shares Out 172.84M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 125,000
Average Volume 62,127
Open 0.0003
Previous Close 0.0003
Day's Range 0.0003 - 0.0003
52-Week Range 0.0000 - 0.1345
Beta 2.27
RSI 47.52
Earnings Date Feb 13, 2026

About Nascent Biotech

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Na... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Sean Carrick
Country United States
Stock Exchange OTCMKTS
Ticker Symbol NBIO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.